{"generic":"Metoprolol Succinate\/Hydrochlorothiazide","drugs":["Dutoprol","Metoprolol Succinate\/Hydrochlorothiazide"],"mono":[{"id":"928586-s-0","title":"Generic Names","mono":"Metoprolol Succinate\/Hydrochlorothiazide"},{"id":"928586-s-1","title":"Dosing and Indications","sub":[{"id":"928586-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Hypertension, Not for initial therapy:<\/b> Initial, metoprolol succinate extended-release 25 mg\/hydrochlorothiazide 12.5 mg ORALLY once daily<\/li><li><b>Hypertension, Not for initial therapy:<\/b> Titration based on blood pressure response, every 2 weeks up to a maximum of metoprolol succinate extended-release 200 mg\/hydrochlorothiazide 25 mg once daily<\/li><li><b>Hypertension, Not for initial therapy:<\/b> Switching from individual components, patient may receive the corresponding dose of metoprolol succinate extended-release\/hydrochlorothiazide<\/li><\/ul>"},{"id":"928586-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"928586-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, severe (CrCl 30 mL\/min or less):<\/b> Safety and effectiveness have not been established<\/li><li><b>renal impairment, moderate (CrCl 30 to 60 mL\/min):<\/b> No adjustment needed<\/li><li><b>hepatic impairment, moderate:<\/b> Initiate therapy with lower doses of hydrochlorothiazide<\/li><li><b>hepatic impairment, mild:<\/b> No dosage adjustment needed<\/li><\/ul>"},{"id":"928586-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hypertension, Not for initial therapy<br\/>"}]},{"id":"928586-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet, Extended Release)<\/b><br\/>Exacerbation of angina and myocardial infarction have occurred after abrupt discontinuation of beta-blocking agents, including patients treated only for hypertension. Avoid abrupt discontinuation of therapy, especially in patients with known ischemic heart disease. To withdraw chronically administered hydrochlorothiazide\/metoprolol succinate, gradually reduce the dosage over 1 to 2 weeks. If angina worsens or acute coronary ischemia develops, promptly reinstate therapy and manage unstable angina.<br\/>"},{"id":"928586-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928586-s-3-9","title":"Contraindications","mono":"<ul><li>anuria<\/li><li>cardiogenic shock or decompensated heart failure<\/li><li>hypersensitivity to hydrochlorothiazide, metoprolol succinate, or to other sulfonamide-derived drugs<\/li><li>second- or third-degree atrioventricular block unless a permanent pacemaker is in place<\/li><li>sinus bradycardia or sick sinus syndrome<\/li><\/ul>"},{"id":"928586-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- exacerbation of angina or myocardial infarction may occur after abrupt discontinuation; monitoring and gradual dose reduction recommended<\/li><li>-- avoid abrupt discontinuation<\/li><li>Cardiovascular:<\/li><li>-- heart failure may worsen during up-titration; dosage reduction or discontinuation may be necessary<\/li><li>--bradycardia, including sinus pause, heart block, and cardiac arrest, have been reported, especially in patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders (eg, Wollf-Parkinson-White); monitoring recommended and discontinuation may be necessary<\/li><li>-- peripheral vascular disease; symptoms of arterial insufficiency may be precipitated or aggravated<\/li><li>Endocrine and Metabolic:<\/li><li>-- electrolyte imbalances (hyponatremia, hypokalemia, hypomagnesemia, hypercalcemia) may occur with thiazide therapy; monitoring recommended<\/li><li>-- glucose tolerance may be altered with thiazide therapy<\/li><li> serum levels of cholesterol and triglycerides may be raised with thiazide therapy<\/li><li>-- hyperuricemia may occur or frank gout may be precipitated with thiazide therapy<\/li><li>-- pheochromocytoma; as beta-blocker monotherapy is associated with a paradoxical increase in blood pressure, initiate alpha-blocking agent prior to use of any beta-blocking agent<\/li><li>-- tachycardia due to hypoglycemia may be masked with beta-blockers<\/li><li>-- thyrotoxicosis; clinical signs of hyperthyroidism may be masked and abrupt withdrawal of beta-blockade may cause a thyroid storm<\/li><li>Hepatic:<\/li><li>hepatic function impairment or progressive liver disease; minor changes in fluid and electrolyte balance may lead to hepatic coma<\/li><li>Ophthalmic:<\/li><li>-- acute angle-closure glaucoma and transient myopia may occur and lead to permanent vision loss, especially in patients with a history of sulfonamide or penicillin allergy; promptly discontinue therapy<\/li><li>Respiratory:<\/li><li>-- bronchospastic diseases; as beta-1-selectivity is not absolute, use lowest dose possible<\/li><li>Renal:<\/li><li>-- acute renal failure may occur in patients with chronic kidney disease, severe heart failure, volume depletion<\/li><li>Other:<\/li><li>-- major surgery; impaired ability to respond to reflex adrenergic stimuli may increase the risks of general anesthesia and surgical procedures<\/li><li>-- noncardiac surgery; initiation of high-dose regimenshould be avoided due to risk of bradycardia, hypotension, stroke, and death in patients with cardiac risk factors<\/li><li>-- systemic lupus erythematosus may be activated or exacerbated<\/li><li>Concomitant use:<\/li><li>-- avoid lithium<\/li><li>-- coadministered antidiabetic drugs may need dosage adjustment<\/li><li>-- reduced effectiveness of epinephrine for treating severe anaphylactic reactions may occur; other medications recommended<\/li><li>--- use with beta adrenergic blockers, digoxin, clonidine, or non-dyhidrophydrine calcium channel blockers (eg, verapamil, diltiazem) increases risk of bradycardia; monitoring recommended and discontinuation may be necessary<\/li><li>-- use with catecholamine-depleting drugs (eg, reserpine, MAO inhibitors) may increase the risk of hypotension or bradycardia; monitoring recommended<\/li><li>-- use with NSAIDs can reduce the diuretic, natriuretic, and antihypertensive efficacy of thiazide therapy<\/li><li>-- use with ion exchange resins (eg, cholestyramine, colestipol resins) reduces absorption of hydrochlorothiazide; stagger dosage<\/li><\/ul>"},{"id":"928586-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928586-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"928586-s-4","title":"Drug Interactions","sub":[{"id":"928586-s-4-13","title":"Contraindicated","mono":"<ul>Dofetilide (probable)<\/ul>"},{"id":"928586-s-4-14","title":"Major","mono":"<ul><li>Acetyldigoxin (established)<\/li><li>Albuterol (theoretical)<\/li><li>Amiodarone (established)<\/li><li>Arformoterol (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Bambuterol (theoretical)<\/li><li>Clenbuterol (theoretical)<\/li><li>Clonidine (theoretical)<\/li><li>Colterol (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclophosphamide (probable)<\/li><li>Deslanoside (established)<\/li><li>Digitalis (established)<\/li><li>Digitoxin (established)<\/li><li>Digoxin (established)<\/li><li>Diltiazem (probable)<\/li><li>Dronedarone (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Fenoldopam (theoretical)<\/li><li>Fenoterol (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Hexoprenaline (theoretical)<\/li><li>Indacaterol (theoretical)<\/li><li>Isoetharine (theoretical)<\/li><li>Ketanserin (theoretical)<\/li><li>Lacosamide (theoretical)<\/li><li>Levalbuterol (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Lidocaine (probable)<\/li><li>Lithium (probable)<\/li><li>Metaproterenol (theoretical)<\/li><li>Methotrexate (probable)<\/li><li>Metildigoxin (established)<\/li><li>Olodaterol (theoretical)<\/li><li>Ouabain (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pirbuterol (theoretical)<\/li><li>Procaterol (theoretical)<\/li><li>Proscillaridin (theoretical)<\/li><li>Reproterol (theoretical)<\/li><li>Ritodrine (theoretical)<\/li><li>Rivastigmine (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Sotalol (probable)<\/li><li>Terbutaline (theoretical)<\/li><li>Tretoquinol (theoretical)<\/li><li>Tulobuterol (theoretical)<\/li><li>Verapamil (probable)<\/li><li>Vilanterol (theoretical)<\/li><\/ul>"},{"id":"928586-s-4-15","title":"Moderate","mono":"<ul><li>Acarbose (probable)<\/li><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Alacepril (probable)<\/li><li>Albiglutide (probable)<\/li><li>Alfuzosin (probable)<\/li><li>Alogliptin (probable)<\/li><li>Amlodipine (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Arbutamine (probable)<\/li><li>Aspirin (probable)<\/li><li>Benazepril (probable)<\/li><li>Bepridil (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Bunazosin (probable)<\/li><li>Canagliflozin (probable)<\/li><li>Captopril (probable)<\/li><li>Carbamazepine (probable)<\/li><li>Celecoxib (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Cholestyramine (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Cilazapril (probable)<\/li><li>Citalopram (probable)<\/li><li>Clonixin (probable)<\/li><li>Dapagliflozin (probable)<\/li><li>Delapril (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Dipyrone (probable)<\/li><li>Doxazosin (probable)<\/li><li>Dulaglutide (probable)<\/li><li>Empagliflozin (probable)<\/li><li>Enalapril (probable)<\/li><li>Enalaprilat (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Exenatide (probable)<\/li><li>Felbinac (probable)<\/li><li>Felodipine (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Fosinopril (probable)<\/li><li>Ginkgo (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Gossypol (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Imidapril (probable)<\/li><li>Indomethacin (probable)<\/li><li>Insulin Aspart, Recombinant (probable)<\/li><li>Insulin Degludec (probable)<\/li><li>Insulin Detemir (probable)<\/li><li>Insulin Glargine, Recombinant (probable)<\/li><li>Insulin Glulisine (probable)<\/li><li>Insulin Human Inhaled (probable)<\/li><li>Insulin Human Isophane (NPH) (probable)<\/li><li>Insulin Human Regular (probable)<\/li><li>Insulin Lispro, Recombinant (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lacidipine (probable)<\/li><li>Lercanidipine (probable)<\/li><li>Licorice (probable)<\/li><li>Linagliptin (probable)<\/li><li>Liraglutide (probable)<\/li><li>Lisinopril (probable)<\/li><li>Lixisenatide (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Manidipine (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Metformin (probable)<\/li><li>Mibefradil (probable)<\/li><li>Miglitol (probable)<\/li><li>Mirabegron (established)<\/li><li>Moexipril (probable)<\/li><li>Morniflumate (probable)<\/li><li>Moxisylyte (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nepafenac (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimesulide (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Pentopril (probable)<\/li><li>Perindopril (probable)<\/li><li>Phenelzine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenoxybenzamine (probable)<\/li><li>Phentolamine (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Pioglitazone (probable)<\/li><li>Piroxicam (probable)<\/li><li>Pramlintide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Prazosin (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propoxyphene (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Quinapril (probable)<\/li><li>Ramipril (probable)<\/li><li>Repaglinide (probable)<\/li><li>Rifampin (probable)<\/li><li>Rifapentine (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Rosiglitazone (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Saxagliptin (probable)<\/li><li>Sitagliptin (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Spirapril (probable)<\/li><li>St John's Wort (probable)<\/li><li>Sulindac (probable)<\/li><li>Tamsulosin (probable)<\/li><li>Telithromycin (probable)<\/li><li>Temocapril (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Terazosin (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Topiramate (probable)<\/li><li>Trandolapril (probable)<\/li><li>Trimazosin (probable)<\/li><li>Urapidil (probable)<\/li><li>Valdecoxib (probable)<\/li><li>Venlafaxine (established)<\/li><li>Vildagliptin (probable)<\/li><li>Zofenopril (probable)<\/li><\/ul>"}]},{"id":"928586-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia<\/li><li><b>Gastrointestinal:<\/b>Nausea<\/li><li><b>Psychiatric:<\/b>Fatigue (2.6%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (3.4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypokalemia<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Aplastic anemia, Hemolytic anemia, Leukopenia, Thrombocytopenia<\/li><li><b>Hepatic:<\/b>Hepatitis, Jaundice<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Ophthalmic:<\/b>Angle-closure glaucoma, acute, Myopia, Acute transient<\/li><li><b>Renal:<\/b>Interstitial nephritis<\/li><li><b>Reproductive:<\/b>Peyronie's disease<\/li><li><b>Respiratory:<\/b>Bronchospasm<\/li><\/ul>"},{"id":"928586-s-6","title":"Drug Name Info","sub":{"0":{"id":"928586-s-6-17","title":"US Trade Names","mono":"Dutoprol<br\/>"},"2":{"id":"928586-s-6-19","title":"Class","mono":"<ul><li>Beta-Adrenergic Blocker, Cardioselective<\/li><li>Beta-Adrenergic Blocker\/Thiazide Combination<\/li><li>Diuretic<\/li><li>Thiazide<\/li><\/ul>"},"3":{"id":"928586-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928586-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"928586-s-7","title":"Mechanism Of Action","mono":"<ul><li>Metoprolol succinate is a beta-adrenergic blocker with selective activity on beta(1) adrenoreceptors located mainly in cardiac muscles. At higher doses, it also inhibits beta(2) adrenoreceptors of bronchial and vascular smooth muscles. The mechanism of the antihypertensive action of beta blockers has not been confirmed but it may include competitive antagonism of catecholamines at peripheral adrenergic neuron sites which leads to decreased cardiac output, a central effect leading to reduced sympathetic outflow to the periphery, and suppression of renin activity.<\/li><li>Hydrochlorothiazide is a thiazide diuretic agent that affects the electrolyte reabsorption at the distal renal tubule resulting in increased excretion of sodium and chloride in equal amounts and indirectly reduces plasma volume. The antihypertensive action of thiazides is still unknown.<\/li><\/ul>"},{"id":"928586-s-8","title":"Pharmacokinetics","sub":[{"id":"928586-s-8-23","title":"Absorption","mono":"<ul><li>Metoprolol succinate, Bioavailability: (Oral, extended-release tablets), approximately 40%<\/li><li>Hydrochlorothiazide, Oral, extended-release: rapid<\/li><li>Hydrochlorothiazide, Bioavailability: (Oral tablets), 60% to 80%<\/li><li>Effect of food: not significant.<\/li><\/ul>"},{"id":"928586-s-8-24","title":"Distribution","mono":"<ul><li>Metoprolol, Protein binding: (Oral, immediate-release), about 12%<\/li><li>Hydrochlorothiazide, Protein binding: about 40% (Beermann &amp; Groschinsky-Grind, 1980).<\/li><\/ul>"},{"id":"928586-s-8-25","title":"Metabolism","mono":"<ul><li>Metoprolol - Hepatic; CYP2D6<\/li><li>Hydrochlorothiazide - None<\/li><\/ul>"},{"id":"928586-s-8-26","title":"Excretion","mono":"<ul><li>Metoprolol, Renal: (oral), less than 5% unchanged<\/li><li>Hydrochlorothiazide, Renal: (oral), 61% unchanged<\/li><\/ul>"},{"id":"928586-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Metoprolol: (oral), 3 to 7 hours<\/li><li>Hydrochlorothiazide: (oral), 6 to 15 hours<\/li><\/ul>"}]},{"id":"928586-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>may split Dutoprol(R) tablets to administer lower doses<\/li><li>may be administered with or without food<\/li><li>avoid abrupt withdrawal of chronically administered therapy; taper over 1 to 2 weeks<\/li><\/ul>"},{"id":"928586-s-10","title":"Monitoring","mono":"<ul><li>reduction (at rest and upon exercise) in heart rate, cardiac output, and systolic and diastolic blood pressure, and reduction of reflex orthostatic tachycardia is indicative of efficacy<\/li><li>serum electrolytes; periodically<\/li><li>creatinine; periodically<\/li><li>calcium levels<\/li><li>liver enzymes and\/or serum bilirubin; periodically<\/li><li>signs and symptoms of exacerbations of angina pectoris and myocardial infarction; when discontinuing therapy, especially in patients with ischemic heart disease<\/li><li>heart rate and rhythm<\/li><\/ul>"},{"id":"928586-s-11","title":"How Supplied","mono":"<b>Dutoprol<\/b><br\/>Oral Tablet, Extended Release: (Hydrochlorothiazide - Metoprolol Succinate) 12.5 MG-25 MG, 12.5 MG-50 MG, 12.5 MG-100 MG<br\/>"},{"id":"928586-s-12","title":"Toxicology","sub":[{"id":"928586-s-12-31","title":"Clinical Effects","mono":"<ul><li><b>BETA-BLOCKING AGENTS <\/b><br\/>USES: Used primarily to treat hypertension.  Also used as a treatment for akathisia, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, stable angina, tachydysrhythmias, thyrotoxicosis, congestive heart failure, congenital heart conditions, and for migraine headache prophylaxis and variceal hemorrhage prophylaxis. Bimatoprost\/timolol and travoprost\/timolol ophthalmic combinations are indicated for the reduction of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma. Refer to beta-blocking agents document for more information. PHARMACOLOGY: Inhibition\/competitive blockade of beta-adrenergic receptors. TOXICOLOGY: The toxicity of beta-blockers is an extension of their therapeutic effects. They cause bradycardia, heart-block and hypotension. Propranolol has sodium channel blocking properties and may cause ventricular dysrhythmias. EPIDEMIOLOGY: Poisoning is uncommon but can be very severe.  May occur via oral, intravenous or ophthalmic administration. MILD TO MODERATE POISONING: Decreased heart rate and hypotension. SEVERE POISONING: Atrioventricular blocks, intraventricular conduction delays, and congestive heart failure can occur with more severe poisoning. Coma and cardiopulmonary arrest can develop secondary to severe hypotension\/bradycardia.  Bronchospasm may develop, particularly in patients with asthma or COPD, and respiratory depression may develop in patients with severe hypotension.  Propranolol is highly lipid-soluble and may cross the blood brain barrier and cause seizures.  Propranolol may cause QRS widening resulting in ventricular dysrhythmias due to sodium channel blockade.  Renal failure and pulmonary edema may develop in patients with prolonged hypotension.  Hypoglycemia may develop in diabetics or those with decreased glycogen stores (eg, children, fasting, exercising); manifestations of hypoglycemia (tremor, tachycardia) may be masked by clinical effects of beta-blocker toxicity. OCULAR EXPOSURE: Ophthalmic preparations containing beta-blockers may cause systemic manifestations. ONSET: Symptoms usually occur within 6 hours, but can be as early as 20 minutes and may be delayed with sustained release products. ADVERSE EFFECTS: Hypotension, bradycardia, first-degree heart block, dizziness, fatigue, depression, pruritus, rash, diarrhea, dyspnea, bronchospasm, hypoglycemia, and seizures are among the adverse effects. Superficial punctate keratitis, corneal erosion, burning sensation, eyelid pruritus, eye dryness, eye pain, photophobia, eye discharge, visual disturbances, eyelid erythema, and blepharal pigmentation have been reported in up to 10% of patients receiving bimatoprost\/timolol ophthalmic solution. Eye pain, ocular discomfort, dry eye, and eye pruritus have been reported in up to 10% of patients receiving travoprost\/timolol maleate (polyquaternium-1-preserved).<br\/><\/li><li><b>DIURETICS<\/b><br\/>USES: Class of drugs that are primarily used to treat hypertension and congestive heart failure. Potassium sparing diuretics and carbonic anhydrase inhibitors are covered in separate managements. PHARMACOLOGY: Work in a variety of mechanisms including inhibiting sodium and chloride reabsorption in the distal convoluted tubule (thiazides), inhibiting transport of sodium, potassium, and chloride in the thick ascending limb of the loop of henle (loop), and osmotic agents (mannitol). TOXICOLOGY: Produce hypovolemia and electrolyte deficiencies. EPIDEMIOLOGY: Rare overdose which uncommonly results in significant morbidity or death. MILD TO MODERATE TOXICITY: Mild dehydration, tachycardia, dry mucous membranes, headache, muscle cramps, thirst, and brisk diuresis. Large doses of furosemide or ethacrynic acid can cause ototoxicity. SEVERE TOXICITY: Hypotension, hypochloremic metabolic alkalosis, mental status changes, and electrolyte abnormalities (i.e. hypokalemia, hypomagnesemia, hypochloremia, hypocalcemia) are the most common manifestations of severe poisoning. Rarely muscle spasms, tetany, seizures, coma, or dysrhythmias may develop secondary to severe electrolyte abnormalities.  CNS depression has been reported rarely in children with acute ingestion without significant electrolyte abnormalities. ADVERSE EFFECTS: Thiazides are associated with hyperglycemia and hyperlipidemia. Furosemide has been associated with ototoxicity, hyperglycemia, and hypercholesterolemia.  Diuretics have a large number of drug interactions as well. Extravasation of mannitol can cause tissue injury and compartment syndrome.<br\/><\/li><\/ul>"},{"id":"928586-s-12-32","title":"Treatment","mono":"<ul><li><b>BETA-BLOCKING AGENTS <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Place patient on a cardiac monitor, give fluids for hypotension, and atropine for bradycardia. MANAGEMENT OF SEVERE TOXICITY: Perform early orotracheal intubation for airway protection if the patient has altered mental status. Initially manage hypotension with intravenous fluids (500 mL boluses up to 2L) and atropine for symptomatic bradycardia. Glucagon should be considered if the patient does not respond appropriately to intravenous fluids. Give catecholamines to those who do not respond to intravenous fluids and glucagon. No one catecholamine has been shown to be consistently effective; dopamine, norepinephrine and epinephrine may be considered. High doses may be required. If catecholamines are required despite glucagon and intravenous fluids, high-dose insulin euglycemia should be considered. Catecholamines should be titrated down when high-dose insulin euglycemia therapy starts to take effect. Intravenous lipid emulsion should be considered in patients with refractory hypotension. Other non-pharmacological therapies include: cardiac pacing, placement of an intraaortic balloon pump, cardiopulmonary bypass, and extracorporeal membrane oxygenation (ECMO). Seizures (rarely progress to status epilepticus) may require aggressive use of benzodiazepines (e.g. 1 to 2 mg lorazepam IV and increase as needed) and\/or propofol. Monitor for dysrhythmias and treat accordingly.<\/li><li>Decontamination: PREHOSPITAL: Activated charcoal if recent, substantial ingestion, and patient able to protect airway. HOSPITAL: Activated charcoal if recent, substantial ingestion, and patient able to protect airway. After airway protection consider gastric lavage in recent, large ingestion, or whole bowel irrigation.<\/li><li>Airway management: Perform early in a patient with severe intoxication (depressed mental status, seizures, dysrhythmias).<\/li><li>Hypotensive episode: Initially manage hypotension with intravenous fluids (500 mL boluses up to 2L) and atropine for symptomatic bradycardia.<\/li><li>Antidote: GLUCAGON: Patients who do not respond to intravenous fluids (500 mL boluses up to 2L) and atropine should be treated with glucagon.  Initial dosing is 5 to 15 mg by slow IV push followed by an infusion rate of 5 to 15 mg\/hour. Glucagon may also induce nausea\/vomiting, as well as elevate blood glucose.<\/li><li>Insulin: High-dose insulin euglycemia (HIS) may be considered in patients who do not respond adequately to fluids and catecholamines. HIS is another potential therapy with some positive animal data and case-based human evidence.  Administer a bolus of 1 unit\/kilogram of insulin followed by an infusion of 0.1 to 1 units\/kilogram\/hour, titrated to a systolic blood pressure of greater than 90 to 100 mmHg (bradycardia may or may not respond). Reassess every 30 minutes to titrate insulin infusion. High-dose insulin euglycemia therapy may allow the practitioner to decrease the dose of catecholamines and avoid the adverse effects of prolonged high dose catecholamines. Before, during, and after the therapy, monitor for hypoglycemia and hypokalemia. Administer dextrose bolus to patients with an initial blood glucose of less than 250 mg\/dL (Adult: 25 to 50 mL dextrose 50%; Children: 0.25 g\/kg dextrose 25%). Begin a dextrose infusion of 0.5 g\/kg\/hour in all patients. Monitor blood glucose every 15 to 30 minutes until consistently 100 to 200 mg\/dL for 4 hours, then monitor every hour. Titrate dextrose infusion to maintain blood glucose in the range of 100 to 200 mg\/dL. As the patient improves, insulin resistance abates and dextrose requirements will increase. Supplemental dextrose will be needed for at least several hours after the insulin infusion is discontinued. Administer supplemental potassium initially if patient is hypokalemic (serum potassium less than 2.5 mEq\/L). Monitor serum potassium every 4 hours and supplement as needed to maintain potassium of 2.5 to 2.8 mEq\/L.<\/li><li>Fat Emulsion: Another potential pharmacological treatment is with lipid emulsion therapy, though at this point in time, there is only animal data supporting its use in beta-blocker toxicity; in theory it may be effective for lipid soluble beta blockers such as propranolol.  The dose of 20% lipid emulsion is 1.5 mL\/kg over 1 minute followed immediately with an infusion at a rate of 0.25 mL\/kg\/min, and to repeat the bolus dosing every 3 to 5 minutes up to 3 mL\/kg total dose until circulation is restored.  If BP declines, increase the infusion rate to 0.5 mL\/kg\/min. A maximum dose of 8 mL\/kg is recommended.  For example, the resuscitation of an adult weighing 70 kg is equivalent to taking a 500 mL bag of 20% lipid emulsion and drawing up 50 mL twice and giving it IV push, and then attaching the infusion bag to an IV and running it in over 15 minutes.<\/li><li>Inamrinone: A phosphodiesterase inhibitor which also has theoretical benefit via decreasing breakdown of myocardial cAMP.  The dosing is 1 mg\/kg bolus then 3 to 6 mcg\/kg\/minute.  It is very rarely used because, although it increases inotropy, it may induce peripheral vasodilation and is difficult to titrate due to a relatively long half-life.<\/li><li>Calcium: Calcium chloride has been effective for propranolol, concurrent administration of atenolol and verapamil, and a mixed metoprolol\/verapamil overdose that were refractory to conventional therapy. Administer calcium chloride 0.2 mL\/kg or calcium gluconate 0.6 mL\/kg intravenously.<\/li><li>Bradycardia: Atropine, glucagon (50-150 mcg\/kg bolus followed by an infusion 1-5 mg\/hr), and pacemaker.<\/li><li>Seizure: Seizures (may rarely progress to status epilepticus) may require aggressive use of benzodiazepines (e.g. 1-2 mg lorazepam IV and increase as needed) and\/or propofol.<\/li><li>Conduction disorder of the heart: QRS widening or ventricular tachycardia may respond to sodium bicarbonate.  A reasonable starting dose is 1 to 2 mEq\/kg bolus, repeat as needed; endpoints include resolution of dysrhythmias, narrowing of QRS complex and blood pH 7.45 to 7.55.  Use lidocaine (1 mg\/kg intravenous bolus followed by 20 to 50 mcg\/kg\/min intravenous infusion) if sodium bicarbonate is not successful.<\/li><li>Monitoring of patient: Monitor vital signs and mental status. Specific beta-blocker plasma levels are not clinically useful or readily available. No specific lab work is needed in most patients. Obtain an ECG and institute continuous cardiac monitoring.  Monitor serum electrolytes and renal function in patients with significant hypotension or dysrhythmias. Monitor blood glucose in children, diabetics, and patients with altered mentation.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion may be useful for beta blockers with small volumes of distribution such as atenolol, sotalol and nadolol; experience is limited to a few case reports.  Hemodialysis and hemoperfusion are not useful  for beta-blockers with large volumes of distribution.<\/li><li>Patient disposition: HOME CRITERIA: Healthy, asymptomatic patients with an inadvertent ingestion of less than or equal to a maximum daily dose for age may be monitored at home. OBSERVATION CRITERIA: Patients with underlying cardiovascular or respiratory disease, those ingesting more than a maximum daily dose, those who co-ingest calcium channel blockers, and those with deliberate overdose of beta-blocking agents should have a baseline ECG and be monitored for a minimum of 6 hours. Patients who develop signs of toxicity during observation should be admitted, while those who are asymptomatic after 6 hours may be discharged, following psychiatric consultation if indicated. Longer observation (at least 8 hours) is required for patients ingesting sustained release products. ADMISSION CRITERIA: Symptomatic patients with cardiovascular symptoms (ie, hypotension, bradycardia) or central nervous system toxicity (ie, somnolence, seizures, coma) should be admitted to an intensive care setting for further observation\/treatment and monitored until they are asymptomatic for a prolonged period (several hours)  without therapy.  CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with toxicity (hypotension, seizures, dysrhythmias), or in whom the diagnosis is not clear.<\/li><\/ul><\/li><li><b>DIURETICS<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients with minor symptoms can be managed with supportive care only.  Oral hydration and oral electrolyte supplementation may be sufficient.  Severe electrolyte disturbances and\/or mental status changes indicate a more severe poisoning. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is very rare. Treatment should be directed at intravenous correction of volume loss and electrolyte abnormalities.<\/li><li>Decontamination: PREHOSPITAL: Prehospital decontamination is not indicated as toxicity is rare. HOSPITAL: Activated charcoal is rarely  indicated as acute toxicity is rare.<\/li><li>Airway management: Diuretic poisoning should not produce symptoms mandating airway management.<\/li><li>Antidote: There is no specific antidote.<\/li><li>Monitoring of patient: Monitor vital signs and serum electrolytes.  Obtain an ECG in patients with significant electrolyte abnormalities.<\/li><li>Enhanced elimination procedure: Hemodialysis is not expected to be helpful.<\/li><li>Patient disposition: HOME CRITERIA: Asymptomatic patients with inadvertent ingestion of less than a maximal daily dose can be monitored at home. OBSERVATION CRITERIA: Adults with intentional ingestions or symptomatic children should be referred to a health care facility.  Patients who are asymptomatic after 6 hours can be discharged home. ADMISSION CRITERIA: Patients who have severe electrolyte abnormalities or vital sign abnormalities should be admitted. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing severe poisonings.<\/li><\/ul><\/li><\/ul>"},{"id":"928586-s-12-33","title":"Range of Toxicity","mono":"<ul><li><b>BETA-BLOCKING AGENTS<\/b><br\/>TOXICITY: The toxic dose is variable depending on the particular agent.  The following ingestions should be considered potentially toxic: ACEBUTOLOL: ADULT: greater than 600 mg; CHILD: greater than 12 mg\/kg. ATENOLOL: ADULT: greater than 200 mg; CHILD: greater than 2 mg\/kg. CARVEDILOL: ADULT: greater than 50 mg; CHILD: greater than 0.5 mg\/kg. LABETALOL: ADULT: greater than 400 mg; CHILD: greater than 20 mg\/kg. METOPROLOL: ADULT: greater than 450 mg IR or greater than 400 mg SR; CHILD: greater than 2.5 mg\/kg IR or greater than 5 mg\/kg SR. NADOLOL: ADULT: greater than 320 mg; CHILD: greater than 2.5 mg\/kg. PROPRANOLOL: ADULT: greater than 240 mg; CHILD: greater than 4 mg\/kg IR, or greater than 5 mg\/kg SR. TIMOLOL: ADULT: greater than 30 mg (tablets); CHILD: any amount.<br\/><\/li><li><b>DIURETICS<\/b><br\/>TOXICITY: Toxic doses are not well established.  Diuresis is expected to result at even therapeutic doses.  Toxicity is most common with chronic dosing and acute toxicity is often related to other factors such as comorbid conditions and access to fluid replacement. THERAPEUTIC DOSE: Furosemide is typically dosed at 20 to 80 mg with repeat doses as necessary in adults; pediatric dose is 1 to 2 mg\/kg orally.  Hydrochlorothiazide is typically dosed at 12.5 to 50 mg daily in adults; pediatric dose is 1 to 3 mg\/kg divided twice daily.<br\/><\/li><\/ul>"}]},{"id":"928586-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>Advise patient to notify physician or dentist of medication use prior to surgical procedures.<\/li><li>This drug may cause nasopharyngitis, fatigue, back pain, nausea, and electrolyte imbalance.<\/li><li>Advise patient to report signs\/symptoms of acute transient myopia associated with acute angle-closure glaucoma, including sudden ocular pain or decreased visual acuity.<\/li><li>Instruct patient to report breathing difficulties or signs\/symptoms of arrhythmias, hypotension, or new or worsening cardiac failure.<\/li><li>Counsel diabetic patient to monitor for signs\/symptoms of hyperglycemia or hypoglycemia and to report difficulties with glycemic control.<\/li><li>Advise patient against sudden discontinuation of drug, as this may exacerbate angina or induce myocardial infarction.<\/li><li>Instruct patient to avoid alcohol while taking drug as orthostatic hypotension may be aggravated.<\/li><li>Warn patient that there are multiple significant drug-drug interactions for this drug and to consult a healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}]}